Global Angiotensin Receptor Blockers (ARBs) Market Revenue and Share Analysis Through 2029

Uncover key drivers, emerging technologies, and competitive movements shaping the angiotensin receptor blockers (arbs) market from 2025–2034 with trusted insights from The Business Research Company

What Is The Projected Valuation Of The Angiotensin Receptor Blockers (ARBs) Market In The Period 2029-2034?

The market for angiotensin receptor blockers (arbs) has experienced consistent growth over recent years. It is projected to increase from $8.51 billion in 2024 to $8.78 billion in 2025, at a compound annual growth rate (CAGR) of 3.1%. The expansion observed historically can be attributed to the hypertension epidemic, proven clinical efficacy, the prevalence of cardiovascular disease, renal protection benefits, established clinical guidelines, the adoption of ARBs as a first-line treatment, and their cost-effectiveness.

The angiotensin receptor blockers (ARBs) market size is projected to experience consistent growth over the coming years. It is expected to expand to $10.52 billion by 2029, achieving a compound annual growth rate (CAGR) of 4.6%. This expansion during the forecast period can be attributed to several factors, including the implementation of precision medicine approaches, an increased focus on combination therapies, the global spread of the market, the use of biomarker-based treatment strategies, various government initiatives, and a greater awareness of hypertension. Prominent trends anticipated in this period include the wider adoption of telemedicine, significant investments in research and development, the effects of generic competition and patent expirations, the development of digital health solutions to enhance medication adherence, and the rise of biosimilar competition.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8943&type=smp

What Strategic Drivers Are Accelerating The Angiotensin Receptor Blockers (ARBs) Market Expansion?

The escalating prevalence of cardiovascular diseases is anticipated to propel the growth of the angiotensin receptor blockers market in the future. Cardiovascular disease (CVD) encompasses any condition impacting the heart or blood vessels. This often correlates with the formation of fatty deposits within arteries (atherosclerosis) and a heightened risk of blood clots. Angiotensin receptor blockers function by reducing blood pressure and enhancing the heart’s pumping capacity through the relaxation of veins and arteries, thereby minimizing the risk of cardiovascular disease. For instance, in August 2022, according to the American College of Cardiology, a US-based professional medical organization, the expected rates of cardiovascular risk factors and disease are projected to considerably rise in the United States by the year 2060. Therefore, the increasing incidence of cardiovascular diseases is driving the growth of the angiotensin receptor blockers market.

What Is The Detailed Segment Distribution Of The Angiotensin Receptor Blockers (ARBs) Market?

The angiotensin receptor blockers (arbs) market covered in this report is segmented –

1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan

2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications

3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Valsartan: Tablets, Capsules, Injectable Forms

2) By Telmisartan: Tablets, Capsules

3) By Losartan: Tablets, Oral Solution

4) By Irbesartan: Tablets, Oral Solution

5) By Azilsartan: Tablets

6) By Olmesartan: Tablets, Oral Suspension

How Are Global Trends Impacting The Development Of The Angiotensin Receptor Blockers (ARBs) Market?

Leading firms within the angiotensin receptor blocker market are creating sophisticated products, including angiotensin receptor neprilysin inhibitors, with the aim of broadening treatment choices and achieving better results for individuals suffering from cardiovascular ailments. Angiotensin receptor neprilysin inhibitors, or ARNIs, represent a category of drugs prescribed for the management of heart failure. As an illustration, in January 2023, Glenmark Pharmaceuticals, a pharmaceutical company based in India, introduced sacubitril + valsartan tablets. These tablets are specifically designed for treating heart failure, particularly focusing on heart failure with reduced ejection fraction (HFrEF). This particular combination is classified within the ARNI (angiotensin receptor neprilysin inhibitors) group of medications. Sacubitril operates by boosting the natriuretic peptide (NP) system, thereby reducing excess fluid and encouraging blood vessel widening, whereas valsartan works by inhibiting the renin-angiotensin system (RAS), which consequently lowers blood pressure and diminishes the demands on the heart. Combined, these two components effectively alleviate heart failure symptoms, lessen the likelihood of cardiovascular death, and decrease hospital admissions stemming from heart failure. These are commercially available under the brand name Sacu V.

Who Are The Major Stakeholders Operating In The Angiotensin Receptor Blockers (ARBs) Market?

Major companies operating in the angiotensin receptor blockers (ARBs) market include Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, Abbvie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/angiotensin-receptor-blockers-arbs-global-market-report

Which Region Is Projected To Achieve The Fastest Growth In The Angiotensin Receptor Blockers (ARBs) Market?

North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2024. The regions covered in the angiotensin receptor blockers (ARBs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=8943&type=smp

Browse Through More Reports Similar to the Global Angiotensin Receptor Blockers (ARBs) Market 2025, By The Business Research Company

Blood And Blood Components Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-and-blood-components-global-market-report

Convalescent Plasma Therapy Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/convalescent-plasma-therapy-global-market-report

Patient Blood Management Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/patient-blood-management-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795